Abbott Laboratories vs Intuitive Surgical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Abbott Laboratories (ABT)

Q3 20265 Jul – 17 Sep 2026

▲3▼1

Abbott's Q3: strong sales, new products, but Exact Sciences deal weighs

Record Q2 sales and raised guidance Abbott reported record second-quarter sales of $12.6 billion, beat expectations, and raised its earnings guidance. Diagnostics grew 42.3% and Medical Devices grew 9%, showing broad strength across the business.
This is the core financial result that drove positive sentiment in the period.
New product approvals and partnerships FDA approved Freenome's colorectal cancer blood test, Abbott partnered with Google Health for Lingo, and won approvals for diabetes and heart devices like Libre Duo and Amulet 360. These expand future revenue streams.
These pipeline advances strengthen Abbott's long-term growth prospects.
Legal clouds ease with settlements Abbott partly settled NEC claims for $670 million and infant-formula claims for $385 million. This reduces legal uncertainty, though about 1,700 NEC lawsuits remain outstanding.
Legal settlements remove overhangs that had pressured the stock.
$21B Exact Sciences deal dilutes guidance Abbott's $21 billion acquisition of Exact Sciences diluted earnings guidance and increased interest expense. While it may boost long-term growth, the near-term financial impact weighed on the stock.
This is the main negative factor that offset positive developments.

September 202623 Aug – 17 Sep 2026

▲4

Abbott's legal clouds clear as new heart and diabetes devices win approvals

FDA clears first dual glucose-ketone sensor Abbott won FDA authorization for Libre Duo 10 Day, the first biowearable that tracks both glucose and ketones, with a U.S. launch planned for later this year. A genuinely new product with no direct rival strengthens Abbott's fast-growing diabetes sensor business and supports a higher stock price.
A first-of-its-kind product approval is a real new growth driver, not a repeat of earlier news.
Two new heart-device approvals widen Abbott's lead Abbott received CE Mark for the Amulet 360 stroke-prevention device and FDA approval for the TactiFlex Duo ablation catheter, its fourth and fifth heart-rhythm approvals in about a year. More approved tools mean more procedures and recurring sales, pushing the stock up.
These are new regulatory wins that expand Abbott's electrophysiology lineup and revenue runway.
Infant formula legal overhang largely resolved Abbott agreed to pay $385 million to settle Department of Justice and state claims over its 2022 Sturgis formula recall, with no finding of fault and the criminal probe closed. Removing this legal cloud lets investors focus on the core business, lifting the stock.
This is a new settlement that clears a major legal risk, a direct positive for the share price.
Citi sees Abbott taking heart-device share from Boston Scientific Citi downgraded rival Boston Scientific, saying it will lose market share in left atrial appendage closure when Abbott's Amulet device launches in 2027. That independent view of Abbott as the winner in a growing market supports the stock.
A fresh analyst call frames Abbott as a competitive gainer, a new reason for optimism.

Latest23 Aug – 17 Sep 2026

▲4

Abbott's legal clouds clear as new heart and diabetes devices win approvals

FDA clears first dual glucose-ketone sensor Abbott won FDA authorization for Libre Duo 10 Day, the first biowearable that tracks both glucose and ketones, with a U.S. launch planned for later this year. A genuinely new product with no direct rival strengthens Abbott's fast-growing diabetes sensor business and supports a higher stock price.
A first-of-its-kind product approval is a real new growth driver, not a repeat of earlier news.
Two new heart-device approvals widen Abbott's lead Abbott received CE Mark for the Amulet 360 stroke-prevention device and FDA approval for the TactiFlex Duo ablation catheter, its fourth and fifth heart-rhythm approvals in about a year. More approved tools mean more procedures and recurring sales, pushing the stock up.
These are new regulatory wins that expand Abbott's electrophysiology lineup and revenue runway.
Infant formula legal overhang largely resolved Abbott agreed to pay $385 million to settle Department of Justice and state claims over its 2022 Sturgis formula recall, with no finding of fault and the criminal probe closed. Removing this legal cloud lets investors focus on the core business, lifting the stock.
This is a new settlement that clears a major legal risk, a direct positive for the share price.
Citi sees Abbott taking heart-device share from Boston Scientific Citi downgraded rival Boston Scientific, saying it will lose market share in left atrial appendage closure when Abbott's Amulet device launches in 2027. That independent view of Abbott as the winner in a growing market supports the stock.
A fresh analyst call frames Abbott as a competitive gainer, a new reason for optimism.

August 20264 Aug – 20 Aug 2026

▲3▼1

Abbott's core growth accelerates as Google deal and NEC settlement reshape outlook

Google Health partnership expands Lingo reach Abbott and Google launched a multi-year partnership to embed Lingo glucose data into the Google Health app, pairing it with AI coaching. This could drive adoption of Abbott's biowearable and open a new consumer health channel, supporting the stock.
New partnership is a fresh growth catalyst for Abbott's diabetes care business.
Instinct sensor powers MiniMed's new insulin pump Abbott is supplying its Instinct sensor for MiniMed's app-controlled insulin pump in the U.S. This broadens Abbott's role in diabetes devices and adds recurring sensor revenue, a positive for the stock.
New product integration expands Abbott's diabetes device footprint.
Medical devices growth driven by electrophysiology and CGM Abbott's medical devices arm is accelerating, with the Volt PFA catheter launching fully and CGM adoption far below its 75-80 million potential users. This long runway supports future revenue growth and a higher stock price.
Highlights durable growth drivers in Abbott's largest device segments.
NEC litigation settled for $670 million, but 1,700 cases remain Abbott agreed to pay about $670 million to settle the Gill case and roughly 2,000 NEC claims, without admitting liability. While this removes a major overhang, about 1,700 lawsuits remain, keeping some legal uncertainty on the stock.
Settlement is a major legal development that reduces but does not eliminate litigation risk.

4 Aug – 20 Aug 2026

▲3▼1

Abbott's core growth accelerates as Google deal and NEC settlement reshape outlook

Google Health partnership expands Lingo reach Abbott and Google launched a multi-year partnership to embed Lingo glucose data into the Google Health app, pairing it with AI coaching. This could drive adoption of Abbott's biowearable and open a new consumer health channel, supporting the stock.
New partnership is a fresh growth catalyst for Abbott's diabetes care business.
Instinct sensor powers MiniMed's new insulin pump Abbott is supplying its Instinct sensor for MiniMed's app-controlled insulin pump in the U.S. This broadens Abbott's role in diabetes devices and adds recurring sensor revenue, a positive for the stock.
New product integration expands Abbott's diabetes device footprint.
Medical devices growth driven by electrophysiology and CGM Abbott's medical devices arm is accelerating, with the Volt PFA catheter launching fully and CGM adoption far below its 75-80 million potential users. This long runway supports future revenue growth and a higher stock price.
Highlights durable growth drivers in Abbott's largest device segments.
NEC litigation settled for $670 million, but 1,700 cases remain Abbott agreed to pay about $670 million to settle the Gill case and roughly 2,000 NEC claims, without admitting liability. While this removes a major overhang, about 1,700 lawsuits remain, keeping some legal uncertainty on the stock.
Settlement is a major legal development that reduces but does not eliminate litigation risk.

July 20265 Jul – 28 Jul 2026

▲3▼1

Abbott beats Q2, raises guidance, but Exact Sciences costs and NEC litigation weigh

Q2 earnings beat and raised guidance Abbott reported record Q2 sales of $12.6 billion, up 13%, and adjusted EPS of $1.31, beating expectations. Management raised full-year EPS guidance to $5.45–$5.60, sending the stock up over 10% initially.
This is the main new event that drove the stock in July.
Medical Devices and Diagnostics growth Medical Devices grew 9%, while Diagnostics surged 42.3% due to the Exact Sciences acquisition. Nutrition trends also improved, showing broad-based strength across Abbott's businesses.
These segment results explain the strong revenue beat and support the positive reaction.
FDA approval of Freenome CRC blood test The FDA approved Freenome's colorectal cancer blood test, which Abbott will exclusively commercialize in the U.S. This adds a new revenue stream and expands Abbott's diagnostic offerings.
This is a new product approval that could drive future growth.
Exact Sciences costs and NEC litigation The $21 billion Exact Sciences deal diluted guidance and spiked interest expense from $50 million to $299 million. Ongoing NEC litigation uncertainty continues to weigh on investor sentiment, keeping a lid on the stock.
These are the main counterweights that prevented even stronger gains.

21 Jul – 28 Jul 2026

▲2▼2

Abbott's Q2 beat and raised guidance offset by Exact Sciences dilution and NEC litigation

Q2 beat and raised guidance Abbott reported record Q2 sales of $12.6 billion, up 13%, and adjusted EPS of $1.31, beating estimates. Management raised full-year adjusted EPS guidance to $5.45–$5.60. This shows the core business is strong and supports a higher stock price.
This is the main positive driver this period, directly boosting investor confidence and the stock's valuation.
FDA approves Freenome CRC blood test, Abbott to commercialize The FDA approved Freenome's SimpleScreen CRC blood test, and Abbott will exclusively sell it in the U.S. starting this fall. This expands Abbott's cancer diagnostics portfolio and adds a new revenue stream, pushing the stock up.
This is a new product approval that directly expands Abbott's diagnostics business and future sales.
Exact Sciences acquisition dilutes guidance and raises interest expense Abbott's $21 billion Exact Sciences acquisition added $919 million in Cologuard sales but also caused interest expense to jump from $50 million to $299 million and diluted full-year guidance. This weighs on the stock as investors worry about the cost of the deal.
This is a key counterweight explaining why the stock hasn't risen more despite strong results.
Ongoing NEC litigation uncertainty Uncertainty around NEC litigation related to Abbott's preterm infant formula continues to weigh on investor sentiment. This legal risk keeps a lid on the stock price, as investors await clarity on potential liabilities.
This is a persistent negative factor that offsets positive business momentum.

5 Jul – 17 Jul 2026

▲3

Abbott beats Q2, raises guidance, stock jumps 11%

Q2 beat and raised full-year guidance Abbott reported Q2 adjusted EPS of $1.31, beating estimates, with sales up 13% to $12.59 billion. Management raised full-year adjusted EPS guidance to $5.45–$5.60 and reaffirmed comparable sales growth of 6.5–7.5%. The stock jumped over 10% as results eased worries about medical devices and nutrition.
This is the main new event that directly drove the stock's sharp move this period.
Medical Devices and Diagnostics strength Medical Devices sales grew 9% to $5.85 billion, led by electrophysiology and diabetes care. Diagnostics surged 42.3% to $3.09 billion after the Exact Sciences acquisition, with cancer diagnostics growing double digits. This shows the core businesses are performing well and supports future growth.
It explains which parts of the business are driving the beat and future optimism.
Nutrition and other segments improving Nutrition sales declined 3.1% but rose sequentially by $125 million, and management expects about 80% of the second-half lift from Nutrition, Electrophysiology, Core Laboratory, and Cancer Diagnostics. Established Pharmaceuticals grew 8.4%. This signals a turnaround in previously weak areas.
It shows the company is addressing prior weaknesses, which supports the raised guidance.

Q2 202620 Jun – 1 Jul 2026

▲4

Abbott's legal cloud lifts, dividend grows, and new products drive optimism

DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.
This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.
Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.
This is a new event that highlights Abbott's financial health and shareholder returns.
New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.
This is a new partnership that opens a new market opportunity for Abbott.
FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.
This is a new catalyst that could accelerate growth in Abbott's diabetes care business.

June 202620 Jun – 1 Jul 2026

▲4

Abbott's legal cloud lifts, dividend grows, and new products drive optimism

DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.
This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.
Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.
This is a new event that highlights Abbott's financial health and shareholder returns.
New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.
This is a new partnership that opens a new market opportunity for Abbott.
FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.
This is a new catalyst that could accelerate growth in Abbott's diabetes care business.

20 Jun – 1 Jul 2026

▲4

Abbott's legal cloud lifts, dividend grows, and new products drive optimism

DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.
This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.
Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.
This is a new event that highlights Abbott's financial health and shareholder returns.
New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.
This is a new partnership that opens a new market opportunity for Abbott.
FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.
This is a new catalyst that could accelerate growth in Abbott's diabetes care business.

Intuitive Surgical Inc (ISRG)

Q3 202629 Jun – 15 Sep 2026

▼3▲1

Intuitive Surgical Beats Q2, But Growth Slows and Competition Heats Up

Q2 Earnings Beat and Strong Recurring Revenue Intuitive Surgical beat Q2 2026 expectations with 19% revenue growth to $2.89 billion and 16% worldwide procedure growth. About 85% of sales are recurring, providing steady income. Free cash flow jumped 71% to $1.8 billion, supporting buybacks and new approvals.
This is the main positive force behind the stock this quarter, showing strong financial performance and cash generation.
U.S. Procedure Growth Slowdown U.S. procedure growth slowed to 12% due to ACA subsidy expirations and GLP-1-driven bariatric declines. This deceleration raises concerns about future growth, making the stock sensitive to any further slowdown headlines.
This is a key negative factor that pressured the stock and highlights a real counterweight to the strong overall results.
Class II Recall and Tariff Threats A Class II recall of 454 da Vinci units and tariff threats pressured margins and shares. These issues add costs and uncertainty, weighing on investor sentiment and profitability.
This is a new negative event that directly impacted margins and stock performance during the quarter.
Intensifying Competition from J&J's Ottava Johnson & Johnson's FDA-approved Ottava robot intensifies competition in robotic surgery. This threatens Intuitive Surgical's market share and pricing power, adding pressure on future growth and the stock.
This is a new competitive development that could erode Intuitive Surgical's dominance and affect long-term growth.

August 202629 Jun – 15 Sep 2026

▲2▼1

Intuitive Surgical Gains on Procedure Growth, Ion Surge, and New Approvals

Strong Procedure and System Growth Worldwide procedures rose 16% and system placements jumped 18% to 468, showing robust demand for da Vinci robots. Recurring revenue now makes up about 85% of sales, providing a steady income base.
This highlights the core operational momentum that drove the stock.
Ion Platform Surge and Cash Flow Growth The Ion platform grew 36%, free cash flow climbed 71% to $1.8 billion, and buybacks plus new approvals like the CE mark for da Vinci SP support growth. Analysts upgraded the stock, and a new Malaysia plant expands Asian capacity.
These are new positive developments that boosted investor confidence.
Rising Competition and U.S. Slowdown Concerns Rising robot competition and concerns about a U.S. slowdown could pressure growth. The stock remains sensitive to any deceleration in headline growth despite its durable recurring-revenue base.
This is the main risk that could weigh on the stock.

Latest29 Jun – 15 Sep 2026

▲4

Intuitive Surgical: Procedure Growth, New Approvals, and Cash Strength Drive Upside

Procedure Growth and System Placements Accelerate Worldwide procedures rose 16% and da Vinci system placements jumped 18% to 468, with U.S. placements up 24%. This shows hospitals are still buying and using Intuitive's robots, which drives recurring revenue and future sales. The stock benefits because growth is durable despite concerns about a U.S. slowdown.
This is the core demand driver that directly supports revenue and earnings growth, which pushes the stock up.
Ion Platform Emerges as Second Growth Engine Ion procedures surged 36% to 48,000, cumulative procedures passed 400,000, and the installed base grew 21% annually. This new lung-cancer diagnosis platform gives Intuitive another source of recurring revenue, reducing reliance on da Vinci and supporting a higher stock valuation.
It highlights a new, fast-growing revenue stream that diversifies the business and boosts long-term growth prospects.
Record Cash Flow Fuels Innovation and Buybacks First-half free cash flow jumped 71% to $1.8 billion, and the company bought back $379 million of stock. Strong cash gives Intuitive flexibility to invest in R&D, expand manufacturing, and return money to shareholders, which supports the stock price by signaling financial health and confidence.
It shows the company's financial strength and ability to fund growth without sacrificing shareholder returns, a key positive for the stock.
Clinical Evidence and New Regulatory Approval Expand Use A landmark meta-analysis showed da Vinci surgery improves outcomes across 13 conditions, and a new CE mark allows transvaginal gynecology with da Vinci SP in Europe. These strengthen the case for adoption, open new markets, and support premium pricing, all of which can lift the stock.
It provides scientific validation and regulatory expansion that can drive broader adoption and pricing power, directly impacting future revenue.

3 Aug – 19 Aug 2026

▲3

ISRG: Solid Procedure Growth and New Products Offset Rising Robot Competition

Recurring revenue and procedure growth remain strong Worldwide procedures rose about 16% and system placements jumped 18% to 468, with recurring instrument and service revenue now roughly 85% of sales. That steady, repeat business supports ISRG's price even when headline growth slows.
Shows the core demand engine still growing, the main support for the stock.
Analyst upgrades and software moat reinforce confidence Oppenheimer upgraded ISRG to Outperform with a $500 target, and UBS called the selloff overdone. The company is rolling out 100+ da Vinci 5 software updates and filed for FDA clearances, deepening its technology lead and supporting the stock.
New analyst actions and product roadmap directly lift investor sentiment and the stock.
New Malaysia plant expands supply for Asia growth ISRG will build a 316,000-square-foot manufacturing facility in Penang, Malaysia, starting operations in 2028 and creating 1,200 jobs. This adds capacity for surgical instruments and supports long-term growth in Asia Pacific, a positive for the stock.
New capacity investment signals confidence and future supply expansion.

July 20261 Jul – 31 Jul 2026

▼3▲1

Intuitive Surgical Q2 Beat Marred by Recall, Slowdown, and New Rival

Q2 Beat and Procedure Growth Intuitive Surgical beat Q2 2026 expectations with revenue up 19% to $2.89 billion, adjusted EPS of $2.80, and 16% worldwide procedure growth. This drove recurring instrument and service revenue, supporting the stock.
This is the main positive fundamental driver for the period.
U.S. Procedure Growth Slowdown U.S. procedure growth slowed to 12% as ACA subsidy expirations left patients uninsured, and GLP-1 drugs reduced bariatric surgeries. This weighed on overall growth and investor sentiment.
This explains a key negative trend affecting demand.
Class II Recall and Tariff Threats A Class II recall of 454 da Vinci units raised regulatory and cost concerns, sending shares down 6.3%. Tariffs also threaten margins, with management warning they could materially alter results.
These are major negative events that pressured the stock.
Competition from J&J's Ottava J&J's FDA-approved Ottava robot now directly challenges da Vinci, threatening market share and pricing power. This competitive threat adds to concerns about future growth.
This is a new competitive development with negative implications.

20 Jul – 31 Jul 2026

▼4

ISRG Plunges on Slowing US Procedures, GLP-1 Headwinds, and New J&J Competition

US Procedure Growth Slows on Insurance and GLP-1 US da Vinci procedure growth slowed to 12% from 14% as ACA subsidy expirations left patients uninsured and GLP-1 weight-loss drugs cut bariatric surgeries. This reduces recurring revenue from instruments and services, pressuring ISRG's stock.
This is the core reason for the stock's decline and the main new negative driver this period.
J&J's Ottava Robot Enters US Market Johnson & Johnson received FDA approval for its Ottava surgical robot, directly challenging Intuitive's da Vinci in soft-tissue surgery. This raises competition and could limit ISRG's market share and pricing power, weighing on the stock.
A new competitive threat that changes the long-term outlook for ISRG's dominance.
Full-Year Procedure Growth Guided to Middle of Range Management said full-year procedure growth will likely be near the middle of its 13.5-15.5% range, not the high end. This disappointed investors who expected stronger growth, leading to a sharp sell-off.
Guidance cut is a key new negative catalyst that drove the stock down.
Tariff Headwinds Could Materially Alter Results Intuitive warned that additional tariffs could materially alter its financial results, adding cost pressure. Tariffs raise expenses for imported components, which can squeeze profit margins and reduce earnings.
Tariff risk is a new explicit warning that adds uncertainty to future profits.

1 Jul – 17 Jul 2026

▼3▲1

Intuitive Beats Q2 but Insurance and Tariff Worries Sink Shares

Q2 Beat on Procedure Growth and da Vinci 5 Placements Intuitive reported Q2 revenue of $2.89 billion, up 19%, and adjusted EPS of $2.80, both beating expectations. Worldwide procedures grew 16%, with 246 da Vinci 5 systems placed. More procedures and system placements drive recurring instrument and service revenue, directly boosting ISRG's sales and profit.
This is the core new financial result that shows the company's underlying business is still growing strongly.
U.S. Procedure Growth Slows on Insurance Changes U.S. da Vinci procedure growth slowed to 12% as patients lost health insurance after ACA tax credits expired. Management warned this could weigh on demand, and analysts cut price targets. Slower U.S. procedure growth means less recurring revenue from instruments and services, pressuring ISRG's stock.
This is the main new negative that caused the stock to drop over 9% despite the earnings beat.
Class II Recall of da Vinci Components Intuitive issued a voluntary Class II recall of certain da Vinci components due to an E-brake retainer pin issue, affecting 454 units. The recall raises operational and regulatory scrutiny, and the stock fell 6.3% on the news. It adds uncertainty ahead of earnings and could lead to higher costs or reputational damage.
This is a new negative event that directly hit the stock price and raises questions about product quality and regulatory risk.
Tariff-Related Margin Pressure Flagged Intuitive maintained its full-year procedure growth outlook of 13.5-15.5% but flagged tariff-related margin pressure. Tariffs add costs to imported components, which can squeeze profit margins. The company also noted a $28 million tariff refund benefit this quarter, but future tariffs remain a headwind.
This is a new cost concern that weighs on profitability and was cited as a reason for the stock's decline.

Q2 202618 Jun – 25 Jun 2026

▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.
This is a new, concrete positive catalyst that directly affects future revenue and earnings.
Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.
This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.
AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.
This is a new angle on how ISRG leverages technology to defend its market leadership.
Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.
This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.

June 202618 Jun – 25 Jun 2026

▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.
This is a new, concrete positive catalyst that directly affects future revenue and earnings.
Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.
This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.
AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.
This is a new angle on how ISRG leverages technology to defend its market leadership.
Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.
This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.

18 Jun – 25 Jun 2026

▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.
This is a new, concrete positive catalyst that directly affects future revenue and earnings.
Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.
This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.
AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.
This is a new angle on how ISRG leverages technology to defend its market leadership.
Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.
This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.